{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T17:29:56Z","timestamp":1762622996875,"version":"build-2065373602"},"reference-count":41,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2006,4,28]],"date-time":"2006-04-28T00:00:00Z","timestamp":1146182400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2006,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>The combination of fludarabine, cyclophosphamide, and rituximab (FC\u2010R) shows significant in vitro synergism and may improve patient outcome with little overlapping toxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Between December 2000 and June 2005, 77 patients completed therapy after a median of 4 cycles of FC\u2010R (fludarabine at a dose of 25 mg\/m<jats:sup>2<\/jats:sup> intravenously [i.v.] on Days 1\u20133, cyclophosphamide at a dose of 250 mg\/m<jats:sup>2<\/jats:sup> i.v. on Days 1\u20133, and rituximab at a dose of 375 mg\/m<jats:sup>2<\/jats:sup> on Day 1). The median age of the patients was 59 years, 65% were male; 31% had previously untreated disease; and 44% had chronic lymphocytic leukemia (CLL), 29% had follicular lymphoma, and 27% other indolent lymphoid malignancies. In addition to standard disease response criteria, patients underwent evaluation using flow cytometric and\/or molecular studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Objective responses (OR) and complete responses (CR) were observed in 83% and 42%, respectively, of evaluable patients (<jats:italic>n<\/jats:italic> = 76), respectively. For patients with CLL, the respective OR and CR rates were 100% and 67% as firstline therapy, and 95% and 14% as salvage therapy. For patients with follicular lymphoma, the respective OR and CR rates were 100% and 86% as firstline therapy, and 87% and 67% as salvage therapy. Responders who had no detectable disease on flow cytometric and\/or molecular studies experienced prolonged remissions with no recurrences reported at a median 25 months of follow\u2010up. Peripheral stem cell collection using stem cell factor plus granulocyte\u2013colony\u2010stimulating factor was successful in 10 of 13 patients who underwent mobilization (77%).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>FC\u2010R is highly active as initial or salvage therapy in patients with CLL or indolent non\u2010Hodgkin lymphoma. Collection of autologous stem cells during molecular remission is feasible and may facilitate future exploration of high\u2010dose therapy in these patients. Cancer 2006. \u00a9 2006 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.21882","type":"journal-article","created":{"date-parts":[[2006,4,28]],"date-time":"2006-04-28T18:21:26Z","timestamp":1146248486000},"page":"2412-2420","source":"Crossref","is-referenced-by-count":81,"title":["Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non\u2010hodgkin lymphoma"],"prefix":"10.1002","volume":"106","author":[{"given":"Constantine S.","family":"Tam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Miles","family":"Prince","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. Henry","family":"Januszewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Westerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine I.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"Carney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,5,18]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"549","volume-title":"Acute Leukemias VII: Experimental Approaches and Novel Therapies","author":"Koehi U","year":"1998"},{"key":"e_1_2_5_3_2","first-page":"655a","article-title":"DNA repair induced by 4\u2010hydroperxycyclophosphamide permits fludarabine nucleotide incorporation and is associated with synergistic induction of apoptosis in quiescent human lymphocytes","volume":"94","author":"Kawai Y","year":"1999","journal-title":"Blood."},{"key":"e_1_2_5_4_2","first-page":"3580","article-title":"DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4\u2010hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine","volume":"7","author":"Yamauchi T","year":"2001","journal-title":"Clin Cancer Res."},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20234"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.5.1414"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2395"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"e_1_2_5_9_2","first-page":"709","article-title":"Inhibition of interleukin 10 by rituximab results in down\u2010regulation of bcl\u20102 and sensitization of B\u2010cell non\u2010Hodgkin's lymphoma to apoptosis","volume":"7","author":"Alas S","year":"2001","journal-title":"Clin Cancer Res."},{"key":"e_1_2_5_10_2","first-page":"5137","article-title":"Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B\u2010non\u2010Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine\/paracrine loop and results in down\u2010regulation of Bcl\u20102 and sensitization to cytotoxic drugs","volume":"61","author":"Alas S","year":"2001","journal-title":"Cancer Res."},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.1997.12.177"},{"key":"e_1_2_5_12_2","first-page":"33","article-title":"Anti\u2010CD20 antibody (IDEC\u2010C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement and caspases","volume":"87","author":"Chow KU","year":"2002","journal-title":"Haematologica."},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03014.x"},{"volume-title":"Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","year":"2001","author":"World Health Organization Classification of Tumours","key":"e_1_2_5_14_2"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa023143"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2003.n.013"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2005.n.040"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.3.791"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602412"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2003.50037"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/100.5.534"},{"key":"e_1_2_5_24_2","first-page":"1672","article-title":"Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation","volume":"90","author":"Ng AP","year":"2005","journal-title":"Haematologica."},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403326"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.051"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.516"},{"key":"e_1_2_5_28_2","first-page":"564","article-title":"Stage IV indolent lymphoma: a randomised study of concurrent vs. sequential use of FND (fludarabine, mitoxantrone, dexamethasone) and rituximab (R) monoclonal antibody therapy, with interferon maintenance","volume":"22","author":"McLaughlin P","year":"2003","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.4.1262"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012551809100"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-129-7-199810010-00010"},{"key":"e_1_2_5_32_2","first-page":"700","article-title":"Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies","volume":"90","author":"Tam C","year":"2005","journal-title":"Haematologica."},{"key":"e_1_2_5_33_2","first-page":"572a","article-title":"Phase II study with fludarabine and cyclophosphamide plus rituximab (FC+R) in relapsed follicular lymphoma patients","volume":"100","author":"Sacchi S","year":"2002","journal-title":"Blood."},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190400029841"},{"issue":"5","key":"e_1_2_5_35_2","first-page":"v95","article-title":"A randomised phase\u2010II study of fludarabine\/cyclophosphamide +\u2010 rituximab in patients with untreated mantle\u2010cell lymphoma","volume":"16","author":"Rule S","year":"2005","journal-title":"Ann Oncol."},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1993.tb00165.x"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.6.2188"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1437"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1258"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1323"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.4.1165"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.021"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.21882","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.21882","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T18:11:19Z","timestamp":1760292679000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.21882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,18]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["10.1002\/cncr.21882"],"URL":"https:\/\/doi.org\/10.1002\/cncr.21882","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2006,5,18]]}}}